Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: a cross-sectional study

In 500 children aged ≤10 years after 13-valent pneumococcal conjugate vaccine (PCV)13 immunisation in different schedules, serotypes 19A-specific and 19F-specific immunoglobulin G (IgG) were predicted to persist above 0.35 µg/mL for ≥10 years in all groups, likely due to PCV13-induced memory with na...

Full description

Saved in:
Bibliographic Details
Published in:Thorax 2020-08, Vol.75 (8), p.689-692
Main Authors: Janapatla, Rajendra Prasad, Hsu, Mei-Hua, Chen, Chyi-Liang, Wei, Sung-Hsi, Yu, Ming-Jia, Su, Lin-Hui, Lin, Tzou-Yien, Chiu, Cheng-Hsun
Format: Article
Language:English
Subjects:
Antibodies
Brief Communication
Cross-sectional studies
Immunoglobulins
Population
Regression analysis
Streptococcus infections
Studies
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 500 children aged ≤10 years after 13-valent pneumococcal conjugate vaccine (PCV)13 immunisation in different schedules, serotypes 19A-specific and 19F-specific immunoglobulin G (IgG) were predicted to persist above 0.35 µg/mL for ≥10 years in all groups, likely due to PCV13-induced memory with natural boosting from residual diseases and colonisation. Generally, serotype-specific IgG could persist above 0.35 µg/mL longer (≥5 years) in the catch-up group than in the 2+1 and 3+1 immunisation groups. 14.5% of the carriage isolates belonged to PCV13 serotypes; statistical analysis revealed that a high serum IgG level (>10.96 µg/mL) will be required to eliminate the point-prevalence nasopharyngeal carriage of serotype 19A.
ISSN:0040-6376
1468-3296
DOI:10.1136/thoraxjnl-2019-213878